[1]
|
Wu, J. and Cai, J. (2021) Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Digestive Diseases and Sciences, 66, 359-368. https://doi.org/10.1007/s10620-020-06183-9
|
[2]
|
Sunami, Y. and Kleeff, J. (2019) Immunotherapy of Pancreatic Cancer. Progress in Molecular Biology and Translational Science, 164, 189-216. https://doi.org/10.1016/bs.pmbts.2019.03.006
|
[3]
|
Banerjee, K., Kumar S, Ross, K.A., Gautam, S., Poelaert, B., Nasser, M.W., et al. (2018) Emerging Trends in the Immunotherapy of Pancreatic Cancer. Cancer Letters, 417, 35-46. https://doi.org/10.1016/j.canlet.2017.12.012
|
[4]
|
Batista, I. and Melo, S. (2019) Exosomes and the Future of Immunotherapy in Pancreatic Cancer. International Journal of Molecular Sciences, 20, Article No. 567. https://doi.org/10.3390/ijms20030567
|
[5]
|
Ren, B., Cui, M., Yang, G., Wang, H., Feng, M., You, L., et al. (2018) Tumor Microenvironment Participates in Metastasis of Pancreatic Cancer. Molecular Cancer, 17, Article No. 108. https://doi.org/10.1186/s12943-018-0858-1
|
[6]
|
Yao, W., Maitra, A. and Ying, H. (2020) Recent Insights into the Biology of Pancreatic Cancer. eBioMedicine, 53, Article ID: 102655. https://doi.org/10.1016/j.ebiom.2020.102655
|
[7]
|
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., et al. (2020) Immunotherapy for Pancreatic Cancer: A 2020 Update. Cancer Treatment Reviews, 86, Article ID: 102016.
https://doi.org/10.1016/j.ctrv.2020.102016
|
[8]
|
Dougan, S.K. (2017) The Pancreatic Cancer Microenvironment. The Cancer Journal, 23, 321-325.
https://doi.org/10.1097/PPO.0000000000000288
|
[9]
|
叶辰, Zheng, L., 原春辉. 胰腺癌免疫微环境及免疫治疗的前景与展望[J]. 中华外科杂志, 2019, 57(1): 10-15.
|
[10]
|
Li, J., Byrne, K.T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity, 49, 178-193.E7.
https://doi.org/10.1016/j.immuni.2018.06.006
|
[11]
|
Leinwand, J. and Miller, G. (2020) Regulation and Modulation of Antitumor Immunity in Pancreatic Cancer. Nature Immunology, 21, 1152-1159. https://doi.org/10.1038/s41590-020-0761-y
|
[12]
|
Melero, I., Berman, D.M., Aznar, M.A., Korman, A.J., Pérez Gracia, J.L. and Haanen, J. (2015) Evolving Synergistic Combinations of Targeted immunotherapies To Combat Cancer. Nature Reviews Cancer, 15, 457-472.
https://doi.org/10.1038/nrc3973
|
[13]
|
Blair, A.B. and Zheng, L. (2017) Rational Combinations of Immunotherapy for Pancreatic Ductal Adenocarcinoma. Chinese Clinical Oncology, 6, Article No. 31. https://doi.org/10.21037/cco.2017.06.04
|
[14]
|
Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L. and Hwu, P, (2012) Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cance. New England Journal of Medicine, 366, 2455-2465.
https://doi.org/10.1056/NEJMoa1200694
|
[15]
|
Camacho, L.H. (2015) CTLA-4 Blockade with Ipilimumab: Biology, Safety, Efficacy, and Future Considerations. Cancer Medicine, 4, 661-672. https://doi.org/10.1002/cam4.371
|
[16]
|
Skelton, R.A., Javed, A., Zheng, L. and He, J. (2017) Overcoming the Resistance of Pancreatic Cancer to Immune Checkpoint Inhibitors. Journal of Surgical Oncology, 116, 55-62. https://doi.org/10.1002/jso.24642
|
[17]
|
Witkiewicz, A., Williams, T.K., Cozzitorto, J., Durkan, B., Showalter, S.L. and Yeo, C.J. (2008) Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection. Journal of the American College of Surgeons, 206, 849-854.
https://doi.org/10.1016/j.jamcollsurg.2007.12.014
|
[18]
|
Manuel, E.R., Chen, J., D’Apuzzo, M., Lampa, M.G., Kaltcheva, T.I. and Thompson, C.B. (2015) Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunology Research, 3, 1096-1107.
https://doi.org/10.1158/2326-6066.CIR-14-0214
|
[19]
|
Holmgaard, R.B., Zamarin, D., Munn, D.H., Wolchok, J.D. and Allison, J.P. (2013) Indoleamine 2,3-Dioxygenase Is a Critical Resistance Mechanism in Antitumor T Cell Immunotherapy Targeting CTLA-4. Journal of Experimental Medicine, 210, 1389-1402. https://doi.org/10.1084/jem.20130066
|
[20]
|
McCormick, K.A., Coveler, A.L., Rossi, G.R., Vahanian, N.N., Link, C. and Chiorean, E.G. (2015) Pancreatic Cancer: Update on Immunotherapies and Algenpantucel-L. Human Vaccines & Immunotherapeutics, 12, 563-575.
https://doi.org/10.1080/21645515.2015.1093264
|
[21]
|
Sahin, I.H., Askan, G., Hu, Z. and O’Reilly, E.M. (2017) Immunotherapy in Pancreatic Ductal Adenocarcinoma: An Emerging Entity? Annals of Oncology, 28, 2950-2961. https://doi.org/10.1093/annonc/mdx503
|
[22]
|
Li, M., Bharadwaj, U., Zhang, R., Zhang, S., Mu, H. and Fisher, W.E., et al. (2008) Mesothelin Is a Malignant Factor and Therapeutic Vaccine Target for Pancreatic Cancer. Molecular Cancer Therapeutics, 7, 286-296.
https://doi.org/10.1158/1535-7163.MCT-07-0483
|
[23]
|
Lepisto, A.J., Moser, A.J., Zeh, H., Lee, K., Bartlett, D., McKolanis, J.R., et al. (2008) A Phase I/II Study of a MUC1 Peptide Pulsed Autologous Dendritic Cell Vaccine as Adjuvant Therapy in Patients with Resected Pancreatic and Biliary Tumors. Cancer Therapy, 6, 955-964.
|
[24]
|
Deguchi, T., Tanemura, M., Miyoshi, E., Nagano, H., Machida, T., Ohmura, Y., et al. (2010) Increased Immunogenicity of Tumor-Associated Antigen, Mucin 1, Engineered to Express Alpha-Gal Epitopes: A Novel Approach to Immunotherapy in Pancreatic Cancer. Cancer Research, 70, 5259-5269. https://doi.org/10.1158/0008-5472.CAN-09-4313
|
[25]
|
Bernhardt, S.L., Gjertsen, M.K., Trachsel, S., Møller, M., Eriksen, J.A., Meo, M., et al. (2006) Telomerase Peptide Vaccination of Patients with Non-Resectable Pancreatic Cancer: A Dose Escalating Phase I/II Study. British Journal of Cancer, 95, 1474-1482. https://doi.org/10.1038/sj.bjc.6603437
|
[26]
|
Wobser, M., Keikavoussi, P., Kunzmann, V., Weininger, M., Andersen, M.H. and Becker, J.C. (2006) Complete Remission of Liver Metastasis of Pancreatic Cancer under Vaccination with a HLA-A2 Restricted Peptide Derived from the Universal Tumor Antigen Surviving. Cancer Immunology, Immunotherapy, 55, 1294-1298.
https://doi.org/10.1007/s00262-005-0102-x
|
[27]
|
Nishida, S., Koido, S., Takeda, Y., Homma, S., Komita, H., Takahara, A., et al. (2014) Wilms Tumor Gene (WT1) Peptide-Based Cancer Vaccine Combined with Gemcitabine for Patients with Advanced Pancreatic Cancer. Journal of Immunotherapy, 37, 105-114. https://doi.org/10.1097/CJI.0000000000000020
|
[28]
|
Yanagimoto, H., Shiomi, H., Satoi, S., Mine, T., Toyokawa, H., Yamamoto, T., et al. (2010) A Phase II Study of Personalized Peptide Vaccination Combined with Gemcitabine for Non-Resectable Pancreatic Cancer Patients. Oncology Reports, 24, 795-801. https://doi.org/10.3892/or_00000923
|
[29]
|
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S. and Onners, B., et al. (2008) Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research, 14, 1455-1463. https://doi.org/10.1158/1078-0432.CCR-07-0371
|
[30]
|
Le, D.T., Wang-Gillam, A., Picozzi, V., Greten, T.F., Crocenzi, T. and Springett, G., et al. (2015) Safety and Survival with GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 33, 1325-1333. https://doi.org/10.1200/JCO.2014.57.4244
|
[31]
|
Le, D.T., Lutz, E., Uram, J.N., Sugar, E.A., Onners, B., Solt, S., et al. (2013) Evaluation of Ipilimumab in Combination with Allogeneic Pancreatic Tumor Cells Transfected with a GM-CSF Gene in Previously Treated Pancreatic Cancer. Journal of Immunotherapy, 36, 382-389. https://doi.org/10.1097/CJI.0b013e31829fb7a2
|
[32]
|
Liu, J., Zhong, J.F., Zhang, X. and Zhang, C. (2017) Allogeneic CD19-CAR-T Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation in B Cell Malignancies. Journal of Hematology & Oncology, 10, Article No. 35.
https://doi.org/10.1186/s13045-017-0405-3
|
[33]
|
Ali, A.I., Oliver, A.J., Samiei, T., Chan, J.D., Kershaw, M.H. and Slaney, C.Y. (2019) Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. Frontiers in Oncology, 9, Article No. 56.
https://doi.org/10.3389/fonc.2019.00056
|
[34]
|
Li, T., Li, H., Li, S., Xu, S., Zhang, W., Gao, H., et al. (2019) Research Progress and Design Optimization of CAR-T Therapy for Pancreatic Ductal Adenocarcinoma. Cancer Medicine, 8, 5223-5231. https://doi.org/10.1002/cam4.2430
|
[35]
|
Jiang, H., Shi, Z., Wang, P., Wang, C., Yang, L., Du, G., et al. (2019) Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. Journal of the National Cancer Institute, 111, 409-418.
https://doi.org/10.1093/jnci/djy134
|
[36]
|
Chen, N., Li, X., Chintala, N.K., Tano, Z.E. and Adusumilli, P.S. (2018) Driving CARs on the Uneven Road of Antigen Heterogeneity in Solid Tumors. Current Opinion in Immunology, 51, 103-110.
https://doi.org/10.1016/j.coi.2018.03.002
|
[37]
|
Posey Jr., A.D., Schwab, R.D., Boesteanu, A.C., Steentoft, C., Mandel, U., Engels, B., et al (2016) Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity, 44, 1444-1454. https://doi.org/10.1016/j.immuni.2016.05.014
|
[38]
|
Golubovskaya, V., Berahovich, R., Zhou, H., Xu, S., Harto, H., Li, L., et al. (2017) CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers, 9, Article No. 139.
https://doi.org/10.3390/cancers9100139
|
[39]
|
Raj, D., Yang, M.H., Rodgers, D., Hampton, E.N., Begum, J., Mustafa, A., et al. (2018) Switchable CAR-T Cells Mediate Remission in Metastatic Pancreatic Ductal Adenocarcinoma. Gut, 68, 1052-1064.
https://doi.org/10.1136/gutjnl-2018-316595
|
[40]
|
Sukumaran, S., Watanabe, N., Bajgain, P., Raja, K., Mohammed, S. and Fisher, W.E. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discovery, 8, 972-987.
https://doi.org/10.1158/2159-8290.CD-17-1298
|
[41]
|
Jiang, J., Zhou, H., Ni, C., Hu, X., Mou, Y. and Huang, D, (2018) Immunotherapy in Pancreatic Cancer: New Hope or Mission Impossible? Cancer Letters, 445, 57-64. https://doi.org/10.1016/j.canlet.2018.10.045
|
[42]
|
Hecht, J.R., Bedford, R., Abbruzzese, J.L., Lahoti, S., Reid, T.R., Soetikno, R.M., et al. (2003) A Phase I/II trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clinical Cancer Research, 9, 555-561.
|
[43]
|
Noonan, A.M., Farren, M.R., Geyer, S.M., Huang, Y., Tahiri, S., Ahn, D., et al. (2016) Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 24, 1150-1158. https://doi.org/10.1038/mt.2016.66
|
[44]
|
Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J.M., Neoptolemos, J., et al. (2015) Addressing the Challenges of Pancreatic Cancer: Future Directions for Improving Outcomes. Pancreatology, 15, 8-18.
https://doi.org/10.1016/j.pan.2014.10.001
|